• Aβ42 Peptide Induces Phagocytic Activation in Murine Microgl

  2026-07-01

  This study establishes that fibrillar Amyloid β-Peptide (1-42) (Aβ42) directly stimulates phagocytic activity in murine microglia in a time- and dose-dependent manner. The findings clarify a mechanistic link between amyloid pathology and microglial immune function, offering new insight for Alzheimer's disease research models.

• SAG (Smoothened Agonist): Precision Engineering of Hedgehog

  2026-07-01

  Explore the advanced scientific foundation and unique protocol insights for Smoothened Agonist (SAG), a potent Smoothened receptor agonist. This article offers a new perspective on Hedgehog pathway activation with practical guidance and critical evaluation of assay innovation.

• TRIM66 Controls Monogenic Olfactory Receptor Expression via

  2026-06-30

  This study identifies TRIM66 as the missing epigenetic repressor that enforces strict monogenic and monoallelic expression of olfactory receptor genes in sensory neurons. The discovery clarifies a longstanding question about how neurons achieve singular receptor identity, with implications for understanding transcriptional regulation in diverse gene families.

• OTUD3 Stabilizes SLC7A11 to Drive Ferroptosis Resistance in

  2026-06-30

  This study uncovers how OTUD3 enhances sunitinib resistance in clear cell renal cell carcinoma (ccRCC) by stabilizing SLC7A11, thereby suppressing ferroptosis. The findings provide mechanistic insight into drug resistance and suggest that targeting OTUD3 or SLC7A11 may enhance therapeutic efficacy.

• Atrial Natriuretic Peptide (ANP), rat: Reliable Assay Soluti

  2026-06-29

  This article addresses real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how 'Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat' (SKU A1009) provides robust, reproducible results for biomedical researchers. Scenario-driven Q&A blocks offer validated guidance on protocol optimization, data interpretation, and vendor selection, positioning APExBIO’s research-grade peptide as a trusted choice for cardiovascular and metabolic studies.

• Anti Reverse Cap Analog: Precision mRNA Capping for Enhanced

  2026-06-29

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, is revolutionizing synthetic mRNA workflows by delivering orientation-specific 5’ capping, doubling translational efficiency, and boosting mRNA stability. Its robust chemical design empowers researchers in mRNA therapeutics, gene editing, and cellular reprogramming, setting a new benchmark for reproducibility and performance.

• Foretinib (GSK1363089): Precision Assays and Cellular Respon

  2026-06-28

  Explore how Foretinib (GSK1363089) enables advanced tumor cell growth inhibition and motility assays. This article offers a unique focus on integrating quantitative in vitro drug response metrics for robust cancer research.

• Norovirus Exploits NINJ1 for Selective NS1 Secretion via Cas

  2026-06-27

  The reference study reveals how murine norovirus co-opts NINJ1, traditionally seen as a cell death effector, to selectively secrete its NS1 protein through a caspase-3–dependent pathway. This work uncovers a novel mechanism of viral immune evasion and advances understanding of regulated DAMP release during infection.

• Amyloid Beta-peptide (25-35): Optimizing Neurotoxicity Model

  2026-06-26

  Amyloid Beta-peptide (25-35) (human) enables precise modeling of Alzheimer's disease neurotoxicity, empowering mechanistic studies of microglial polarization and amyloid aggregation. This article provides workflow guidance, troubleshooting, and translational insights rooted in recent advances on the FLOT1–FOSL2–EphA2 axis.

• KG-501 as a Precision Tool for Dissecting CREB/CBP-Driven Tu

  2026-06-26

  Explore how KG-501, a potent inhibitor of CREB-mediated transcription, uniquely enables detailed analysis of immune-tumor interactions by disrupting transcriptional coactivator networks. This article uncovers advanced applications and practical assay guidance, distinguishing itself with deep insights into immune modulation in cancer.

• Valemetostat: Dual EZH1/2 Inhibition in Adult T-cell Leukemi

  2026-06-25

  This article reviews the first approval of valemetostat, a dual EZH1/2 inhibitor, for treating aggressive adult T-cell leukemia/lymphoma (ATL), a malignancy with historically poor prognosis. The paper’s findings highlight the clinical rationale, mechanistic insight, and therapeutic implications of dual targeting histone methyltransferases in hematologic cancers.

• NDRG2–DRP1 Axis Drives Mitochondrial Fission in Pulmonary Hy

  2026-06-25

  This study uncovers that NDRG2 directly interacts with DRP1, promoting its phosphorylation and mitochondrial fission, which accelerates pulmonary vascular remodeling in pulmonary hypertension (PH). Targeting the NDRG2–DRP1 pathway could open new avenues for reversing disease progression, as current therapies fail to address underlying structural changes.

• DNase I (RNase-free): Optimizing DNA Removal in RNA Workflow

  2026-06-24

  DNase I (RNase-free) from APExBIO enables high-purity RNA isolation, precise chromatin digestion, and reliable RT-PCR sample prep. Discover the enzyme’s protocol flexibility, troubleshooting strategies, and how recent innovations in pain research inform best practices for DNA removal.

• (R,S)-Anatabine for Soluble Aβ Reduction in Alzheimer's Mode

  2026-06-23

  (R,S)-Anatabine provides researchers with a potent, well-characterized tool for soluble Aβ peptide reduction, enabling reproducible workflows in both in vitro and in vivo Alzheimer's disease models. This guide translates recent mechanistic insights and experimental best practices into a practical roadmap for maximizing the compound’s impact in neurodegeneration research.

• Targeting Cdc42 to Mitigate Kidney Fibrosis: Insights from R

  2026-06-23

  A recent study identifies Cdc42 as a direct target for reducing kidney fibrosis, demonstrating that inhibition of the Cdc42-mediated GSK-3β/β-catenin pathway effectively suppresses fibroblast activation and extracellular matrix deposition. This work provides a mechanistic rationale for the use of selective Cdc42 inhibitors in translational renal fibrosis research.

7921 records 7/529 page Previous Next First page 上5页 678910 下5页 Last page